Background Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with
activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or …

RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged≥ 65 years …

PURPOSE Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was
evaluated in this global, multicenter, randomized, open-label, phase III study in patients with …

Background The BCL2 inhibitor venetoclax has shown activity in patients with chronic
lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with …

Abstract Background Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment
of chronic lymphocytic leukemia (CLL) in 2014. Ibrutinib is often used to treat patients who …

Mutational analyses performed following acquired ibrutinib resistance have suggested that
chronic lymphocytic leukemia (CLL) progression on ibrutinib is linked to mutations in Bruton …

Abstract Purpose of Review Chronic lymphocytic leukemia (CLL) is a common hematologic
malignancy in elderly patients. At the time of diagnosis, most patients have comorbid …

Purpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis
syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an …

The ALLIANCE A041202 trial found that continuously administered ibrutinib in the first-line
setting significantly prolonged progression-free survival compared with a fixed-duration …

Novel agents, including Bruton tyrosine kinase inhibitors (BTKis), have become the standard
of care for patients with chronic lymphocytic leukemia (CLL). We conducted a real-world …